ChromoCure Rebrands Corporate Image and Realigns Operations to Reflect Its Pioneering Role in Cancer Detection, Therapy and Cure
2010年2月22日 - 10:30PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the official
launch of its realigned business strategy and its corporate
rebranding. The Company recently announced its accelerated Therapy
and Cure initiatives through the launch of Project Boveri: Find the
Cure; and the new branding properly reflects its pioneering role in
cancer detection, therapy and cure; and its increased research
programs and collaborations. Learn more about the company's new
branding and initiatives at www.ChromoCure.com.
As recently announced the Company realigned its business
strategy due to corroboration by recent Medical Research
publications that both validated ChromoCure's
chromosomal/aneuploidy theory of cancer and immediately established
the company's proprietary ChromoSomal Scanner technology in the
forefront of both cancer detection and research.
Research has conclusively, and irrefutably demonstrated
aneuploidy as a more accurate predictor of cancer than
cytological/histological analysis or genetic marker-based
diagnostics that are the only other methods in existence today.
ChromoCure's proprietary technology and understanding of cancer
also suggest non-toxic and non-invasive approaches to cancer
therapy and cure research.
The company's technology and research combined with unique
insights provided by the chromosomal theory of cancer paves the way
for non-invasive and non-toxic solutions to cancer therapeutics and
disease eradication. ChromoCure's ChromoSomal Scanner Technologies,
encompassing proprietary designs, processes, and algorithms,
provides significant advantage in delivering important and
significant results in diagnosis therapy and cure.
Supported by recent third party medical findings, the Company
launched its collaborative research approach with its "Project
Boveri: Find the Cure" initiative; and is inviting industry,
institutions, medical research centers and government to partner in
this initiative. The company has already established a special
section of its web site dedicated to this project and research
outreach. The Company's recently announced diagnostic partnership
program with pathologists and diagnostic labs will be incorporated
into Project Boveri in order to broaden awareness of the company's
technology.
The company will soon announce various collaborative research
agreements as well as progress reports on new partnerships,
products, licensing, and laboratory activities based on its
research-oriented alignment.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and technologies. The Company's proprietary ChromoCure
CS200 Chromosomal Scanner system has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's detection technology has been proven to have an effective
accuracy of 100% for all cancers at all stages. The Company
believes its technology will become the worldwide gold standard for
cancer detection, progression measurement, and research for both
therapy and cure.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024